In a recent issue of the ARCHIVES,1 we reported lower fracture risk among women taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) for hypercholesterolemia. The research was prompted by the finding that statins increase bone morphogenetic protein-2, leading to osteoblast differentiation and bone formation.2 The substantial 60% reduction in fracture risk we reported persisted after adjusting for potential confounders and was greater than expected from increases observed in bone mineral density alone.
Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Falls and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Arch Intern Med. 2002;162(20):2381. doi: